Anti-VEGF Gains Ground in PDR - Summary - MDSpire

Anti-VEGF Gains Ground in PDR

  • May 28, 2026

Share

Objective:

To compare the efficacy and safety of intravitreal brolucizumab versus panretinal photocoagulation (PRP) in treatment-naïve patients with proliferative diabetic retinopathy (PDR).

Key Findings:
  • Brolucizumab showed a mean gain of 0.2 letters in best-corrected visual acuity (BCVA), while PRP resulted in a decline of 4.2 letters, indicating a significant difference of 4.4 letters.
  • 63.6% of patients treated with brolucizumab had no evidence of PDR at week 54 compared to 22.4% in the PRP group.
  • Rates of center-involved diabetic macular edema (CI-DME) were lower with brolucizumab (31.1%) compared to PRP (72.7%).
  • Overall ocular adverse events were less frequent in the brolucizumab group (34.3%) compared to PRP (49.1%).
Interpretation:

Limitations:
  • Intraocular inflammation, including retinal vasculitis, was observed in 5.2% of brolucizumab-treated patients.
  • The study primarily focused on treatment-naïve patients, which may limit generalizability.
Conclusion:

Original Source(s)

Anti-VEGF Gains Ground in PDR

  • May 28, 2026

Related Content

Myopia Management: Treat the Growing Eye, Not Just the Prescription

When to start, what to measure, how to monitor, and when to adjust course

Accelerating Peer Learning in Eye Care

Lumenis launches peer-to-peer learning program aimed at developing practical strategies for modern-day practice

  • May 27, 2026

  • 2 min
Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min